Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 With Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

Next Previous
Trial Profile

A Three-part, Phase I/II Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 With Subsequent Extension of Optimal Dose in Recurrent GBM Subjects

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VBI 1901 (Primary) ; VBI 1901 (Primary) ; AS01B; Carmustine; Granulocyte macrophage colony stimulating factor; Lomustine
  • Indications Glioblastoma
  • Focus Adverse reactions; First in man
  • Sponsors VBI Vaccines

    • Most Recent Events

    • 03 Apr 2024 According to VBI vaccine media release,, for phase 2b, 14 leading neuro-oncology centers are actively recruiting patients across the United States, 2 new clinical sites were activated in March 2024, with a third site expected to come online in April, Patient enrollment in Q1 2024 was double the enrollment rate observed in Q4 2023
    • 03 Apr 2024 Results presented at VBI vaccine media release
    • 03 Apr 2024 Results presented at World Vaccine Congress 2024 on April 3, 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top